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Early 1,25-dihydroxyvitamin D3 (VD3) therapy during the
course of renal failure prevents the downregulation of VD3
receptor (VDR), calcium-sensing receptor (CaSR) or p21, and
the parathyroid (PT) growth. We hypothesized that VD3 could
restore the decreased expressions of VDR and CaSR, and
cause regression in enlarged PT glands. 5/6 nephrectomized
rats fed high-phosphorus diet were killed at 1, 3, 5, or 7 days
and at 2, 3, 4, 8, or 12 weeks. VD3-treated rats were given VD3
intraperitoneally for 1, 2, 3, or 4 weeks, starting 8 weeks after
5/6 nephrectomy. PT glands were weighed and subjected to
immunohistochemical analyses for VDR, CaSR, p21, Ki67, and
Tdt-mediated dUTP nick end-labeling (TUNEL) assay. The area
per cell was measured as the parameter of cell size. The
expression of VDR and p21 began to decrease at day 1, and
Ki67 increased at day 3, but decreased thereafter. There was
a significant increase in PT gland weight to week 12 with the
increase of cell size. VD3 treatment significantly increased
both VDR and CaSR expressions 2 weeks after the start of
injection, and reduced the PT gland weight at week 3 with
significant increase of TUNEL-positive cells and decrease of
cell size. Our results suggest that PT growth in uremic rats
involves both PT cell proliferation and hypertrophy, in
association with the reduction of VDR, CaSR, and p21
expressions. In addition, VD3 treatment could reverse PT
hyperplasia and hypertrophy via restoration of these
proteins.
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Secondary hyperparathyroidism is an inevitable complication
of chronic renal failure. It is characterized by an increase in
the synthesis and secretion of parathyroid hormone (PTH),
mainly due to disturbances of calcium (Ca), phosphate (Pi),
and 1,25-dihydroxyvitamin D3 (VD3) metabolism. It is also
known that a continuous increase in PTH production is
associated with parathyroid (PT) hyperplasia. The expression
of VD3 receptor (VDR) correlates negatively with the
proliferative activity of PT glands in patients with secondary
hyperparathyroidism.1 Liu et al.2 defined a functional VD3-
responsive element within the p21 promoter mediating this
induction. In human PT glands, we demonstrated that the
reduced expression of p21, in a VDR-dependent manner, is a
pathogenic factor for nodular PT glands in uremic patients
with secondary hyperparathyroidism, by using immunohisto-
chemical analyses.3 Ca-sensing receptor (CaSR) may also play
a role in the regulation of PT hyperplasia.4 Naveh-Many
et al.5 revealed that Ca deprivation, together with VD3
deficiency, resulted in marked enhancement of the prolife-
rative activity of PT glands in uremic rats, using the
proliferating cell nuclear antigen. In this regard, Ho et al.6
reported that CaSR knockout mice had enlarged PT glands.
Moreover, Wada et al.7 indicated that administration of the
calcimimetic compound NPS R-568, a CaSR agonist, led to
the suppression of PT cell proliferation in experimental
uremic rats. These reports suggest that the downregulation of
either VDR or CaSR could play a crucial role in the
pathogenesis of PT growth in secondary hyperparathyroid-
ism. The first aim of the present study was to assess the
pathogenesis of PT growth, by examining the time course of
VDR, CaSR, and p21 expressions immunohistochemically.
Low expressions of VDR, CaSR, and p21 were observed in
the PT glands of experimental uremic rats with secondary
hyperparathyroidism.4,5,8 Denda et al.9 reported that early
administration of VD3 prevented the reduction of VDR.
Cozzolino et al.10 showed that VD3 treatment induced p21
expression in hyperplastic PT glands in a model of early
uremia. VD3 has been known to prevent cell proliferation and
enhance cell maturation. These effects were initially described
in lymphoid cells2 and more recently in keratinocytes and
myocytes.11–13 The importance of VD3 in the PT hyperplasia
of experimental uremic rats was first described by Szabo
et al.14 They were able to inhibit PT cell proliferation
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completely when VD3 was administered at the start of
uremia, but not when given later (21 days after 5/6
nephrectomy). However, Reichel et al.15 could observe a
reduction of PT gland weight by intermittent administration
of VD3 on the 21st day of uremia. Fukagawa et al.
16
demonstrated that pharmacological doses of VD3 repressed
c-myc expression in the PT glands of uremic rats and
suggested that VD3 might suppress PT hyperplasia through
this pathway. They also reported the regression of PT
hyperplasia in hemodialysis patients by VD3 pulse therapy.
17
In contrast, Quarles et al.18 reported the failure of VD3
treatment to reduce PT hyperplasia in hemodialysis patients.
It remains controversial whether VD3 could induce regression
of enlarged PT glands. Thus, in the present study, we
hypothesized that VD3 could restore the decreased VDR,
CaSR, and p21 expressions with a resultant regression of PT
hyperplasia.
RESULTS
Protocol 1
Biochemical determinations and PT gland weight. Table 1
shows serum concentrations of creatinine (Cr), Ca, Pi, PTH
and VD3 in normal control rats (NR) and uremic rats for
all experimental conditions tested (UR-1w, 2w, 3w, 4w). After
5/6 nephrectomy, the serum concentration of Cr increased
from week 1–3 and then decreased. In almost all uremic rats,
a compensatory renal hypertrophy was observed at post
mortem, which was considered to be the cause of the
improved renal function (figure not shown). Serum Ca
concentrations significantly decreased after partial nephrec-
tomy, probably due to the elevated Pi levels. Changes in PTH
levels were similar to those of Cr. PTH was significantly high
from 2 weeks after 5/6 nephrectomy (Po0.01), but decreased
in week 4. The serum level of VD3 was significantly decreased
in almost all uremic rats compared to NR.
Expressions of VDR, CaSR and p21 proteins. We examined
immunohistochemical staining for VDR, CaSR, and p21
protein in PT glands resected from rats of the corresponding
experimental groups. Immunohistochemical staining for
VDR and p21 protein revealed mainly nuclear localization.
CaSR protein was detected in the cell membrane and
cytoplasm. Representative pictures are shown in Figure 1.
The labeling index (LI) of each group is depicted in Table 2.
For the normal group, many cells showed positive nuclear
staining for VDR protein (Figure 1a). VDR-positive cells
decreased time dependently. In the UR-4w group, few VDR-
positive cells were noted (Figure 1d). VDR-LI diminished
significantly 1 week after partial nephrectomy compared with
NR (Po0.01, Table 2). The expression of CaSR protein was
enhanced in the PT glands of NR (Figure 1b). CaSR-LI also
decreased in a time-dependent manner from week 1 like
VDR-LI. In NR, many cells showed positive staining with p21
protein (Figure 1c) and the number of positively stained cells
decreased gradually. The p21-LI also decreased significantly
from week 1. VDR-LI, CaSR-LI, and p21-LI significantly
negatively correlated with PT gland weight (Po0.01,
r¼0.40, 0.62, and 0.65, respectively), but not with
Ki67-LI.
PT hyperplasia and hypertrophy. PT glands were weighed
after removal of all thyroid tissue surrounding the glands.
Table 1 | Biochemical determinations: protocol 1
Group n Cr (mg/dl) Ca (mg/dl) Pi (mg/dl)
Intact PTH
(pg/ml) VD3 (pg/ml)
NR 9 0.2870.01 10.470.1 9.770.2 5877 310716
UR-1w 7 0.8470.09* 9.170.2* 11.370.7 279735** 69725*
UR-2w 7 0.9770.19* 8.370.4* 12.170.8** 5777125* 128735*
UR-3w 7 1.0470.11* 8.270.4* 10.971.0 7247116* 88730*
UR-4w 7 0.8770.15* 8.370.6* 9.470.6 6987171* 136735*
Cr, serum creatinine; Ca, serum calcium; Pi, inorganic serum phosphate; PTH,
parathyroid hormone; VD3, 1,25-dihydroxyvitamin D3; NR, normal control rats; UR,
uremic rats fed high-phosphorus diet for 1, 2, 3 or 4 weeks; *Po0.01, **Po0.05 vs
NR group; data are expressed as the mean7s.e.m.
Table 2 | PTG weight, LI of VDR, CaSR, p21 protein and Ki67
antigen expression and the CS index in PTG tissues resected
from each experimental group: protocol 1
Group
PTG weight
(mg) CaSR-LI VDR-LI p21-LI Ki67-LI
CS index
(lm2)
NR 0.2370.03 37.271.6 340779 672744 2972 11177
UR-1w 0.3470.04 18.271.8* 111722* 277712* 87714* 12074
UR-2w 0.3870.06** 15.070.5* 62714* 190731* 7079* 12875
UR-3w 0.7770.06* 11.471.0* 48734* 179766* 58717 151717**
UR-4w 0.8170.09* 8.270.8* 51711* 142721* 5679 15377*
PTG, parathyroid gland, LI, labeling index; VDR, 1,25-dihydroxyvitamin D3 receptor;
CaSR, calcium-sensing receptor; CS, cell size; NR, normal control rats; UR, uremic rats
fed high-phosphorus diet for 1, 2, 3 or 4 weeks; *Po0.01, **Po0.05 vs NR group;
data are expressed as the mean7s.e.m.
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Figure 1 | Typical immunohistochemical findings of VDR, CaSR,
and p21 protein expression in PT tissues resected from (a–c) NR
and (d–f) UR-4w. VDR in UR-1d, CaSR in UR-5d, and p21 in UR-1d are
shown in (g–i), respectively (original magnification 400). (a, d, g)
VDR and (c, f, i) p21 proteins showed mainly nuclear localization.
(b, e, h) CaSR protein showed cell-membranous or cytosolic
localization. The expression levels of these proteins decreased in a
time-dependent manner after the onset of renal failure.
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The PT gland weight increased in a time-dependent manner
after the onset of renal failure (Table 2). The gland weight of
uremic rats increased significantly from week 3 (Po0.01).
Immunohistochemical staining for Ki67 antigen revealed
mainly nuclear localization (figure not shown). The expres-
sion of Ki67 antigen was immediately enhanced after 5/6
nephrectomy (within 1 week) but diminished thereafter
(Table 2). The cell size (CS) index, which is the parameter of
CS, increased significantly from 3 weeks after 5/6 nephrect-
omy. PT gland weight did not correlate with Ki67-LI, but
correlated significantly with the CS index (Po0.01, r¼ 0.55).
There was significant correlation between the CS index and
either CaSR-LI (Po0.01, r¼0.63) or serum Pi levels
(Po0.01, r¼ 0.44).
Protocol 2
Expressions of VDR, CaSR, p21 proteins, and Ki67 antigen. To
assess if the changes in VDR, CaSR, and p21 proteins precede
the onset of PT cell proliferation, we examined the time
course of these proteins and Ki67 antigen within 7 days.
Table 3 shows the labeling indices of each protein and PT
gland weight in the experimental rats. Ki67-LI, as well as PT
gland weight, significantly increased in day 3 (Po0.01,
Figure 2). Both VDR-LI and p21-LI reduced from day 1
significantly (Po0.05, each; Figure 1g, i). On the other hand,
CaSR-LI decreased from day 5 (Figure 1h), which was later
than the start of cell proliferation. Within first 7 days after the
onset of renal failure, there was no change in the CS index.
Protocol 3
Previous reports did not confirm that VD3 treatment could
induce regression of hyperplastic PT glands or restoration of
VDR, CaSR, and p21 expression.14–16,18–21 In the present
study, 5/6 nephrectomized rats fed high-phosphorus diet for
8 weeks were treated with VD3 for 1, 2, 3, or 4 weeks (UVD-
9w, -10w, -11w, or -12w).
Biochemical determinations. Table 4 shows serum con-
centrations of Cr, Ca, Pi, PTH, and VD3 in sham-operated
control rats (Sx-12w), uremic control rats (UR-8w and -12w)
and VD3-treated rats (UVD-9w, -10w, -11w, and -12w). In all
UVD rats, serum Cr concentrations did not differ as
compared to UR-8w and UR-12w. After the VD3 admini-
stration, Ca concentration increased and Pi level decreased
(but not significantly). PTH level in UVD-12w was
significantly lower than in UR-8w and UR-12w (Po0.05,
each). Serum VD3 concentrations increased significantly 2
weeks after start of the administration. We also measured the
serum VD3 concentration at 1, 2, 3, 6, 12, 24, and 48 h after
the injection in UR-8w (15-week-old, n¼ 8). The serum VD3
concentration reached its peak level at 12 h and its
concentration returned to the baseline level within 48 h (data
not shown).
Expressions of VDR, CaSR, p21 proteins and Ki67 anti-
gen. Figure 3 depicts the immunohistochemical staining
of VDR, CaSR, and p21 protein in Sx-12w, UR-12w, and
UVD-12w rats. VD3 treatment enhanced the expression
levels of all proteins. The LIs of these proteins are shown in
Table 5. Both VDR-LI and CaSR-LI were significantly
enhanced at 2 weeks after the start of treatment (Po0.01,
Table 4 | Biochemical determinations: protocol 3
Group n
Cr
(mg/dl)
Ca
(mg/dl)
Pi
(mg/dl)
Intact PTH
(pg/ml)
VD3
(pg/ml)
Sx-12w 7 0.3270.03 9.570.1 6.670.2 3174 252718
UR-8w 6 0.8870.10 9.570.3 7.570.6 5287129 170756
UR-12w 8 0.9070.19 9.770.1 6.670.2 3977137 150712
UVD-9w 5 0.7370.04 9.970.1 6.970.2 205784 205716
UVD-10w 5 0.7270.08 9.870.2 6.270.5 263777 230718##
UVD-11w 8 0.8470.09 10.370.1** 6.670.3 152735**,## 221728##
UVD-12w 9 0.7870.06 9.970.1 6.270.3* 191777**,## 244724**,#
Cr, serum creatinine; Ca, serum calcium; Pi, inorganic serum phosphate; PTH,
parathyroid hormone; VD3, 1,25-dihydroxyvitamin D3; Sx, sham-operated rats; UR,
uremic rats fed high-phosphorus diet for 8 or 12 weeks; UVD, uremic rats given
vitamin D intraperitoneally for 1, 2, 3 or 4 weeks, starting 8 weeks after 5/6
nephrectomy; *Po0.01, **Po0.05 vs UR-8w group; #Po0.01, ##Po0.05 vs UR-12w
group; Data are expressed as the mean7s.e.m.
a b
Figure 2 | Representative immunohistochemical findings of Ki67
antigen in PT tissues resected from (a) NR (b) UR-3d (original
magnification  400). Ki67-positive cells obviously increased 3 days
after 5/6 nephrectomy.
Table 3 | PTG weight, LI of VDR, CaSR, p21 protein and Ki67 antigen expression and the CS index in PTG tissues resected from
each experimental group: protocol 2
Group PTG weight (mg) CaSR-LI VDR-LI p21-LI Ki67-LI CS index (lm2)
NR 0.2370.03 37.271.6 340779 672744 2972 11177
UR-1d 0.2770.02 37.373.0 240732** 4667126** 51713 10775
UR-3d 0.4670.09** 30.973.9 209753* 295773* 237715* 10173
UR-5d 0.4170.05 20.271.4* 175740* 281772* 137716* 9676
UR-7d 0.3470.04 18.271.8* 111722* 277712* 87714* 12074
PTG, parathyroid gland, LI, labeling index; VDR, 1,25-dihydroxyvitamin D3 receptor; CaSR, calcium-sensing receptor; CS, cell size; NR, normal control rats; UR, uremic rats fed
high-phosphorus diet for 1, 3, 5 or 7 days; *Po0.01, **Po0.05 vs NR group; data are expressed as the mean7s.e.m.
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each) and p21-LI was at 4 weeks (Po0.05), compared with
UR-8w. These LIs were significantly higher in UVD-12w
than those in UR-12w (Po0.01, each). Four weeks after the
start of VD3 treatment (UVD-12w), Ki67-LI significantly
decreased (Po0.01).
PT regression. VD3 treatment resulted in a significant
reduction of PT gland weight at week 3 (Table 5). To
elucidate whether the VD3-induced reduction in the volume
of hyperplastic PT glands is associated with cell death or
reduction of hypertrophy, we counted the number of Tdt-
mediated dUTP nick end-labeling (TUNEL)-positive cells
and measured the average area per cell, expressing as CS
index, in randomly selected areas on each specimen
(Figure 3). TUNEL-LI in UVD-12w was significantly higher
than in UR-8w and -12w (Po0.01, each; Table 5). In the
UVD group, the CS index decreased gradually after the start
of VD3 administration (Table 5 and Figure 3). These results
indicate that VD3 treatment can lead not only to cell death,
but also to reduction of cell hypertrophy.
DISCUSSION
The first major finding of the present study was that reduced
expressions of VDR and p21 preceded the start of PT cell
proliferation, during the course of renal failure in the 5/6
nephrectomized rats (Table 3). While the reduction of
VDR and CaSR in enlarged PT glands of uremic patients
and models has already been described,1,3,4,22–25 it is not
clear whether the reduced expression levels of VDR or CaSR
lead to PT cell proliferation. We previously reported that
the VDR-dependent reduction of p21 expression contributes
to the pathogenesis of PT hyperplasia in hemodialysis
patients with secondary hyperparathyroidism.3 In the present
study of uremic rat model, significant decreases of both VDR
and p21 expressions occurred 1 day after 5/6 nephrectomy,
while the PT hyperplasia started at day 3. These results
suggest that the downregulation of both VDR and p21 may
play a crucial role in the pathogenesis of PT hyperplasia
during the course of secondary hyperparathyroidism. This
conclusion was confirmed by the finding that the expression
of VDR and p21 correlated negatively with PT gland weight
(Po0.01, each; figure not shown). On the other hand, the
decrease of CaSR (day 5) was later than the increase of Ki67
antigen (day 3), which was concordant with Ritter et al.’s26
report. This result indicates that the reduction of CaSR may
be the result of PT cell phenotypic change. However, the CaSR
reduction might contribute to further PT growth. The PT
hyperplasia is found in severe neonatal hyperparathyroidism,
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Figure 3 | Representative immunohistochemical findings of VDR,
CaSR, and p21 protein expression in PT tissues resected from
(a, d, g) Sx-12w, (b, e, h) UR-12w, and (c, f, i) UVD-12w (original
magnification 400). (j–l) Cell death was identified by TUNEL assay
and microscopic findings of PT tissues (m–o; hematoxylin staining) in
each group (original magnification 400). The expression levels of
VDR, CaSR and p21 proteins were upregulated after VD3 treatment.
Note the marked increase in TUNEL-positive cells in (l) UVD-12w
compared with (k) UR-12w. The CS in UVD-12w (Figure 1o)
diminished compared with UR-12w (Figure 1n).
Table 5 | PTG weight, LI of VDR, CaSR, p21 protein, Ki67 antigen expression and TUNEL-positive cells and the CS index in PTG
tissues resected from each experimental group: protocol 3
Group PTG weight (mg) CaSR-LI VDR-LI p21-LI Ki67-LI TUNEL-LI CS index (lm2)
Sx-12w 0.4270.04 29.771.7 317717 288727 1372 371 10673
UR-8w 0.8970.06 7.370.4 5779 82713 3273 472 15079
UR-12w 0.9870.04 5.870.5 54717 56712 3072 973 14074
UVD-9w 0.8570.03 9.770.5# 73719 108719 2873 573 14678
UVD-10w 0.8370.07 13.470.7*,# 138722*,# 111719 3074 572 13974
UVD-11w 0.7270.14**,## 15.770.5*,# 190720*,# 121720## 2575 972 11974*,##
UVD-12w 0.7170.07*,# 19.371.6*,# 193713*,# 184731*,# 1973*,## 3675*,# 11375*,#
PTG, parathyroid gland, LI, labeling index; VDR, 1,25-dihydroxyvitamin D3 receptor; CaSR, calcium-sensing receptor; TUNEL, Tdt-mediated dUTP nick end labeling; CS, cell size;
Sx, sham-operated rats; UR, uremic rats fed high-phosphorus diet for 8 or 12 weeks; UVD, uremic rats given vitamin D intraperitoneally for 1, 2, 3 or 4 weeks, starting 8 weeks
after 5/6 nephrectomy; *Po0.01, **Po0.05 vs UR-8w group; #Po0.01, ##Po0.05 vs UR-12w group; data are expressed as the mean7s.e.m.
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a disease attributed to loss-of-function mutations in the CaSR
gene,27 and in the CaSR knockout mice.6 Wada et al.7
demonstrated that a calcimimetic compound NPS R-568
inhibited PT cell proliferation in partial nephrectomized rat
model. Under these circumstances, it is possible that PT cell
proliferation triggers a cascade of events that lead to
downregulation of CaSR and then this CaSR reduction
accelerates PT growth.
The second major finding was that the PT growth in
experimental rat model not only involves PT cell prolifera-
tion but also PT cell hypertrophy. In the present study, Ki67
increased within 1 week after 5/6 nephrectomy (Table 3) and
then decreased in a time-dependent manner (Table 2). In
spite of the reduction in Ki67, PT growth continued. The
gradual increase in the CS index (Table 2) might be the cause
of persistent PT enlargement. Many previous reports have
shown that the hyperplasia begins within 1 week following
partial nephrectomy and high-phosphorus diet.8,10,28,26
However, there was no report indicating the relationship
between PT enlargement and cell hypertrophy. Nagano et al.29
reported that the regression of cell hypertrophy was the
mechanism of regression of PTH growth by sevelamer
hydrochloride administration. This report suggests that the
serum Pi concentration might be related to the mechanism of
PT cell hypertrophy. In our protocol 1, the significant
correlation between the CS index and serum Pi levels was
concordant with Nagano et al.’s report.
The third finding of the present study was that VD3
administration reduced the volume of the enlarged PT glands
and restored the diminished VDR, CaSR, and p21 expression
levels. In our data, TUNEL-positive cells increased and
the CS index decreased significantly by VD3 treatment
(Table 5). These results suggest that VD3 treatment could
induce both PT cell death and reduction of cell hypertrophy.
Previous reports demonstrated that administration of
active VD3 early in the course of renal failure prevented
PT hyperplasia.9,10,15 Our results showed for the first time
that VD3 administration caused regression of enlarged PT
glands during the course of renal failure. There is controversy
regarding the effect of VD3 treatment on PT gland size in
some clinical studies. Using ultrasonography, Fukagawa
et al.17 reported a significant regression of PT hyperplasia
in hemodialysis patients following 12-week VD3 pulse
therapy. In contrast, Quarles et al.18 reported failure of
36-week intermittent intravenous or oral VD3 treatment
to reduce PT hyperplasia in hemodialysis patients, as
examined by ultrasonography and/or magnetic resonance
imaging. The difference between these two reports
suggests that small PT glands such as diffuse hyperplasia
are more likely to undergo reduction in their size than
larger glands. Using percutaneous maxacalcitol injection
therapy technique, Shiizaki et al.19 also demonstrated PT
regression by induction of apoptosis in hemodialysis patients
with secondary hyperparathyroidism. Our results were
concordant with Shiizaki et al.’s report and, furthermore,
indicated that the improvement of hypertrophy might also
play an important role in PT regression. The reduction of
both cell number and cell volume may be involved in PT
regression.
Previous studies reported that early VD3 therapy during
the course of renal failure inhibits the downregulation of
VDR, CaSR and p21.9,10,15 We indicated that VD3 could
restore the expression levels of VDR, CaSR, and p21 in
enlarged PT glands. With regard to CaSR, the presence of
VD3 response element in the upstream of CaSR gene was
confirmed by Canaff and Hendy.30 Liu et al.2 reported that
p21WAF1,CIP1 gene was transcriptionally activated by VD3 in a
VDR-dependent, but p53-independent, manner and defined
a functional VD3 response element within the p21 promoter
mediating this induction. In the present study, the upregula-
tion of both VDR and CaSR preceded the reduction of PT
gland weight, Ki67, and the CS index, and the increase of
TUNEL-positive cells (Table 4). In this regard, restoration of
both VDR and CaSR may contribute not only to arrest PT
hyperplasia but also to PT cell death or reduction of cell
hypertrophy through certain pathways.
In conclusion, our results suggest that PT growth in
uremic rats involves both PT cell hyperplasia and hyper-
trophy, in association with the reduction of VDR, CaSR, and
p21 expressions. In addition, VD3 treatment may induce
reversal of PT hyperplasia and hypertrophy via restoration of
these proteins.
MATERIALS AND METHODS
Study design
The study was conducted in male Sprague–Dawley rats (age 6 weeks,
body weight 4200 g). All rats were killed under ether anesthesia.
For 5/6 nephrectomy, 2/3 of the left kidney was cut and the right
kidney was excised. In protocol 1, the rats were divided at random
into the following experimental groups: NR, 6-week-old, as control
(n¼ 9); uremic rats fed high-phosphorus diet (Ca 1.0%, Pi 0.8%,
VD3 240 IU/100 g; Kyudo Co. Ltd, Saga, Japan) for 1, 2, 3, and 4
weeks (UR-1w (n¼ 7), UR-2w (n¼ 7), UR-3w (n¼ 7) and UR-4w
(n¼ 7), respectively). The high-phosphorus diet was selected based
on the previous study of Slatopolsky et al.31 To examine if the
changes in VDR, CaSR, and p21 precede the onset of PT cell
proliferation, in protocol 2, the rats were divided as follows: NR,
6-week-old, as control (n¼ 9); uremic rats that were killed 1, 3, 5,
and 7 days after 5/6 nephrectomy (UR-1d (n¼ 7), UR-3d (n¼ 7),
UR-5d (n¼ 7) and UR-7d (n¼ 7), respectively).
In protocol 3, the rats were divided into the following groups:
sham-operated rats as control (Sx-12w (19-week-old, n¼ 7));
uremic control rats fed high-phosphorus diet for 8 and 12 weeks
(UR-8w (15-week-old, n¼ 7) and UR-12w (19-week-old, n¼ 10),
respectively). VD3-treated rats were fed the high-phosphorus diet
mentioned above for 12 weeks, and then treated with VD3 (8 ng/kg
body weight, twice per week) for 1, 2, 3, and 4 weeks from 9th week
(UVD-9w (n¼ 5), UVD-10w (n¼ 5), UVD-11w (n¼ 5) and UVD-
12w (19-week-old, n¼ 6: the same age as Sx-12w and UR-12w),
respectively). VD3 was administered intraperitoneally in 0.5 ml
phosphate-buffered saline. The dose of VD3 was based on the study
of Finch et al.32
Blood was withdrawn immediately and placed in ice and the
plasma was kept at 801C for later analysis. PT glands were
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surgically removed and weighed on a GR-202 microbalance (AND
Co., Tokyo, Japan). The harvested PT glands were kept in 10%
formaldehyde overnight and then transferred into 70% ethanol in
water. This experiment was reviewed by the Ethics Committee of
Animal Experimentation, Faculty of Medicine, Kyushu University
and carried out under the Guidelines for Animal Experiments of the
Faculty of Medicine, Kyushu University and the law (no. 105) and
notification (no. 6) of the government.
Biochemical determinations
Serum Cr, Ca, and Pi were measured using an autoanalyzer (Hitachi
Instruments, Tokyo, Japan). Intact PTH levels were determined by
an immunoradiometric assay specific for intact rat PTH (Immuno-
topics Inc., San Clemente, CA, USA). The level of VD3 was
measured by the 1,25(OH)2D RIA kit (Immunodiagnostic Systems,
Boldon, UK).
Immunohistochemistry
All specimens were fixed in 10% formalin and were routinely
processed to paraffin. Formalin-fixed, paraffin-embedded tissue
sections were serially cut at 3 mm and mounted on aminopropyl-
triethoxysilane-coated glass slides. These sections were deparaffi-
nized in xylene and dehydrated through an ethanol series. We
carried out the immunohistochemical staining using previously
described methods.3 The sections were treated with 10 mM citrate,
pH 6.0, in a microwave oven for antigen retrieval before
immunohistochemical staining. The serial sections were then
incubated with the primary antibodies at 41C overnight. The
antibodies used included anti-VDR antibody (Santa Cruz Biotechno-
logy Inc., CA, USA), anti-CaSR antibody (Affinity Bioreagents Inc.,
CO, USA), anti-p21 antibody (Santa Cruz Biotechnology) and anti-
Ki67 antibody (Novocastra Laboratories Ltd, Newcastle, UK).
Immunostaining was performed with the Elite avidin biotin
peroxidase kit (Nichirei, Tokyo, Japan) according to the specifica-
tions provided by the manufacturer. For counting, all of immuno-
histochemical analyses were performed with serial sections.
Tdt-mediated dUTP nick end-labeling assay
Fragmented DNA was detected in cell nuclei using a modification of
previously described methods.33 Each paraffin section of PT tissues
was deparaffinized, dehydrated, blocked with 0.3% H2O2 in
methanol for 30 min at room temperature and then treated with
50 ml of TUNEL reaction mixture (10 Tdt 5 ml, 1 nucleotide
mixture 45ml, in situ detection kit, peroxidase; Roche, Mannheim,
Germany) and incubated in a humidity chamber at 371C for 1 h.
Subsequently, 50 ml converter POD (anti-fluorescein antibody, Fab
fragment from sheep, conjugated with horseradish peroxidase) was
applied to each specimen, and the slides were incubated for 30 min
at 371C in a humidified chamber. After the reaction with converter
POD, the sites of horseradish peroxidase were visualized with 3,
3-diaminobenzidine and H2O2. Slides were counterstained with
methyl green for 2 min.
Quantitation
The quantitative method was described previously.3 Only distinct
immunostaining for CaSR, VDR, p21, Ki67, and TUNEL was
considered positive immunoreactivity. The distribution of immu-
noreactivity was analyzed by quantifying positive staining in
randomly selected areas on each specimen without prior knowledge
of either diagnosis or outcome. The number of cells expressing
VDR, p21, Ki67, and TUNEL were determined by counting a
minimum of 1000 cells per slide using NIH image analysis freeware.
The brightness and contrast of each image were uniformly enhanced
or diminished by Adobe Photoshop version 5.0 followed by analysis
using NIH image freeware version 1.62. With regard to VDR, p21,
Ki67, and TUNEL staining, in order to avoid the influence of non-
specific positive staining, plots of less than 30 pixels were excluded.
The percentage of positive immunoreactive area per total area
(CaSR) and the number of positive immunoreactive nuclei per 1000
parenchymal cells (VDR, p21, Ki67, TUNEL) were expressed as the
LI. CaSR, VDR, p21, Ki67, and TUNEL immunoreactive cells were
randomly counted over a minimum of five fields in more than three
sections. Repeat recounts for CaSR, VDR, Ki67, and TUNEL in 10%
of the PT glands conducted in a blind fashion showed variability of
LIs of p75% from the original counts.
Measurement of cell size
To elucidate cell hypertrophy, the average area per cell was expressed
as the CS index by using the hematoxylin staining section:
CS index ðmm2=cellÞ ¼ T ðmm2Þ=N; where T is the total area per
visual field and N the total number of PT cells per visual field.
Statistical analysis
Data are expressed as mean7s.e.m. All statistics were analyzed by
using the StatView program (Abacus Concepts, Berkeley, CA, USA).
One-way analysis of variance followed by Student’s t-test with
Bonferroni correction was used when indicated for comparison of
each experimental group. A linear regression analysis was also used
for the relationship between each parameter. A P-value less than 0.05
was considered statistically significant.
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